A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: Implications for ADHD and its treatment

Natalia Del Campo; Tim D. Fryer; Young T. Hong; Rob Smith; Laurent Brichard; Julio Acosta-Cabronero; Samuel R. Chamberlain; Roger Tait; David Izquierdo; Ralf Regenthal; Jonathan Dowson; John Suckling; Jean Claude Baron; Franklin I. Aigbirhio; Trevor W. Robbins; Barbara J. Sahakian; Ulrich Müller

doi:10.1093/brain/awt263

A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: Implications for ADHD and its treatment

Natalia Del Campo^*, Tim D. Fryer, Young T. Hong, Rob Smith, Laurent Brichard, Julio Acosta-Cabronero, Samuel R. Chamberlain, Roger Tait, David Izquierdo, Ralf Regenthal, Jonathan Dowson, John Suckling, Jean Claude Baron, Franklin I. Aigbirhio, Trevor W. Robbins, Barbara J. Sahakian, Ulrich Müller

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

89 Citations (SciVal)

Original language	English
Pages (from-to)	3252-3270
Number of pages	19
Journal	Brain
Volume	136
Issue number	11
DOIs	https://doi.org/10.1093/brain/awt263
Publication status	Published (VoR) - Nov 2013

Funding

This work was funded by a Pathfinder Award of the UK Medical Research Council [MRC, G0401099] and the Behavioural and Clinical Neuroscience Institute [BCNI], jointly funded by MRC and Wellcome Trust [MRC Ref G001354 and WT Ref 076244/ Z/04/Z]. N.D.C. was funded by the Gates Cambridge Trust when the work here presented was completed and is now employed by Cambridge Cognition. S.R.C. consults for Cambridge Cognition, P1Vital, and Shire Pharmaceuticals. T.W.R. is a consultant for Cambridge Cognition, Pfizer, Eli Lilly, GlaxoSmithKline, Allon Therapeutics, and Lundbeck, and receives royalties from Cambridge Cognition and Springer-Verlag. B.J.S. consults for Cambridge Cognition and holds shares in CeNeS. She has consulted for Novartis, Shire, GlaxoSmithKline, Eli Lilly and Boehringer-Ingelheim. She also receives an honorarium from the Journal of Psychological Medicine. U.M. has received research and educational grant support from Janssen-Cilag and honoraria or travel expenses from Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Pharmacia-Upjohn, and UCB Pharma.

Keywords

Attention deficit/hyperactivity disorder
Dopamine
Methylphenidate
Sustained attention

Access to Document

10.1093/brain/awt263

Cite this

Del Campo, N., Fryer, T. D., Hong, Y. T., Smith, R., Brichard, L., Acosta-Cabronero, J., Chamberlain, S. R., Tait, R., Izquierdo, D., Regenthal, R., Dowson, J., Suckling, J., Baron, J. C., Aigbirhio, F. I., Robbins, T. W., Sahakian, B. J., & Müller, U. (2013). A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: Implications for ADHD and its treatment. Brain, 136(11), 3252-3270. https://doi.org/10.1093/brain/awt263

@article{d4b86ff2e08e4b5e9bb383aaa04cd610,

title = "A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: Implications for ADHD and its treatment",

keywords = "Attention deficit/hyperactivity disorder, Dopamine, Methylphenidate, Sustained attention",

author = "\{Del Campo\}, Natalia and Fryer, \{Tim D.\} and Hong, \{Young T.\} and Rob Smith and Laurent Brichard and Julio Acosta-Cabronero and Chamberlain, \{Samuel R.\} and Roger Tait and David Izquierdo and Ralf Regenthal and Jonathan Dowson and John Suckling and Baron, \{Jean Claude\} and Aigbirhio, \{Franklin I.\} and Robbins, \{Trevor W.\} and Sahakian, \{Barbara J.\} and Ulrich M{\"u}ller",

note = "Funding Information: This work was funded by a Pathfinder Award of the UK Medical Research Council [MRC, G0401099] and the Behavioural and Clinical Neuroscience Institute [BCNI], jointly funded by MRC and Wellcome Trust [MRC Ref G001354 and WT Ref 076244/ Z/04/Z]. N.D.C. was funded by the Gates Cambridge Trust when the work here presented was completed and is now employed by Cambridge Cognition. S.R.C. consults for Cambridge Cognition, P1Vital, and Shire Pharmaceuticals. T.W.R. is a consultant for Cambridge Cognition, Pfizer, Eli Lilly, GlaxoSmithKline, Allon Therapeutics, and Lundbeck, and receives royalties from Cambridge Cognition and Springer-Verlag. B.J.S. consults for Cambridge Cognition and holds shares in CeNeS. She has consulted for Novartis, Shire, GlaxoSmithKline, Eli Lilly and Boehringer-Ingelheim. She also receives an honorarium from the Journal of Psychological Medicine. U.M. has received research and educational grant support from Janssen-Cilag and honoraria or travel expenses from Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Pharmacia-Upjohn, and UCB Pharma.",

year = "2013",

month = nov,

doi = "10.1093/brain/awt263",

language = "English",

volume = "136",

pages = "3252--3270",

journal = "Brain",

issn = "0006-8950",

publisher = "Oxford University Press",

number = "11",

}

Del Campo, N, Fryer, TD, Hong, YT, Smith, R, Brichard, L, Acosta-Cabronero, J, Chamberlain, SR, Tait, R, Izquierdo, D, Regenthal, R, Dowson, J, Suckling, J, Baron, JC, Aigbirhio, FI, Robbins, TW, Sahakian, BJ & Müller, U 2013, 'A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: Implications for ADHD and its treatment', Brain, vol. 136, no. 11, pp. 3252-3270. https://doi.org/10.1093/brain/awt263

TY - JOUR

T1 - A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention

T2 - Implications for ADHD and its treatment

AU - Del Campo, Natalia

AU - Fryer, Tim D.

AU - Hong, Young T.

AU - Smith, Rob

AU - Brichard, Laurent

AU - Acosta-Cabronero, Julio

AU - Chamberlain, Samuel R.

AU - Tait, Roger

AU - Izquierdo, David

AU - Regenthal, Ralf

AU - Dowson, Jonathan

AU - Suckling, John

AU - Baron, Jean Claude

AU - Aigbirhio, Franklin I.

AU - Robbins, Trevor W.

AU - Sahakian, Barbara J.

AU - Müller, Ulrich

N1 - Funding Information: This work was funded by a Pathfinder Award of the UK Medical Research Council [MRC, G0401099] and the Behavioural and Clinical Neuroscience Institute [BCNI], jointly funded by MRC and Wellcome Trust [MRC Ref G001354 and WT Ref 076244/ Z/04/Z]. N.D.C. was funded by the Gates Cambridge Trust when the work here presented was completed and is now employed by Cambridge Cognition. S.R.C. consults for Cambridge Cognition, P1Vital, and Shire Pharmaceuticals. T.W.R. is a consultant for Cambridge Cognition, Pfizer, Eli Lilly, GlaxoSmithKline, Allon Therapeutics, and Lundbeck, and receives royalties from Cambridge Cognition and Springer-Verlag. B.J.S. consults for Cambridge Cognition and holds shares in CeNeS. She has consulted for Novartis, Shire, GlaxoSmithKline, Eli Lilly and Boehringer-Ingelheim. She also receives an honorarium from the Journal of Psychological Medicine. U.M. has received research and educational grant support from Janssen-Cilag and honoraria or travel expenses from Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Pharmacia-Upjohn, and UCB Pharma.

PY - 2013/11

Y1 - 2013/11

KW - Attention deficit/hyperactivity disorder

KW - Dopamine

KW - Methylphenidate

KW - Sustained attention

UR - https://www.scopus.com/pages/publications/84890489405

UR - https://www.scopus.com/inward/citedby.url?scp=84890489405&partnerID=8YFLogxK

U2 - 10.1093/brain/awt263

DO - 10.1093/brain/awt263

M3 - Article

C2 - 24163364

AN - SCOPUS:84890489405

SN - 0006-8950

VL - 136

SP - 3252

EP - 3270

JO - Brain

JF - Brain

IS - 11

ER -

A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: Implications for ADHD and its treatment

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this